What are the dosing guidelines, contraindications, and monitoring recommendations for lacosamide in adults with focal (partial‑onset) seizures?

Lacosamide Dosing, Contraindications, and Monitoring for Focal Seizures in Adults

Lacosamide should be initiated at 100 mg/day (50 mg twice daily) and titrated weekly by 100 mg/day increments to a target maintenance dose of 200-400 mg/day, with 400 mg/day providing the optimal balance of efficacy and tolerability for most patients with focal seizures 1.

Dosing Guidelines

Initial Dosing and Titration

• Starting dose: 100 mg/day (50 mg twice daily) 2
• Titration schedule: Increase by 100 mg/day weekly 1
• Target maintenance dose: 200-400 mg/day 1
• Maximum dose: 600 mg/day (though 400 mg/day shows similar efficacy with better tolerability) 1

The evidence demonstrates that 400 mg/day provides the best efficacy-to-tolerability ratio, with median seizure frequency reductions of 37.3% compared to 20.8% for placebo 1. While 600 mg/day showed similar overall efficacy (37.8% reduction), it was associated with substantially higher discontinuation rates (28.6% vs 17.2% at 400 mg/day) 3.

Monotherapy Considerations

For monotherapy use (FDA-approved in 2014), the median effective dose in long-term studies was 500 mg/day, with patients maintaining treatment for a median of 587 days 4. Approximately 69% of patients achieved successful 12-month monotherapy at this dose range 4.

Loading Dose Option

A loading dose regimen is available (approved 2013-2014) for situations requiring rapid therapeutic levels, though specific dosing details should follow current FDA labeling 5.

Pharmacokinetic Advantages

Lacosamide has several favorable characteristics that simplify dosing:

• 100% oral bioavailability up to 800 mg 5
• Linear pharmacokinetics with predictable blood concentrations 6
• Half-life of 13-16 hours allowing twice-daily dosing 5
• Low protein binding (<15%) minimizing interaction potential 5
• No food effect on absorption 5

Contraindications and Precautions

Cardiac Monitoring Requirements

ECG monitoring is essential in patients with cardiac disease or conduction abnormalities, as lacosamide is associated with rhythm and conduction disturbances 7. This is a critical safety consideration that distinguishes lacosamide from many other antiseizure medications.

Psychiatric Screening

Avoid lacosamide in patients with significant psychiatric history, or implement intensive monitoring to detect early signs of psychosis or depression 7. If use is necessary in this population, close surveillance is mandatory.

Allergy History

Exercise caution in patients with drug allergy history, as lacosamide can cause DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) and other severe allergic manifestations 7.

Monitoring Recommendations

Routine Monitoring

While lacosamide generally does not require intensive therapeutic drug monitoring (TDM) due to its predictable pharmacokinetics 6, specific populations warrant closer attention:

TDM is indicated for:

• Patients taking enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital) due to significant drug interactions 6
• Severe renal dysfunction or dialysis patients 6
• Elderly patients (≥65 years) 6
• Pregnancy (though more evidence needed) 6

Reference range: 2.2-20 mg/L (though not well-established) 6

Laboratory Monitoring

• Serum sodium: Periodic monitoring recommended (risk of hyponatremia, particularly relevant for patients also on eslicarbazepine) 7
• Renal function: Important given renal elimination pathways 6

Clinical Monitoring

• Seizure frequency: Document baseline and track response
• Adverse effects: Particularly during titration phase when most common
• ECG: Baseline and periodic in at-risk cardiac patients 7

Common Adverse Effects

The most frequent adverse effects are dose-related and predominantly occur during titration 3:

• Dizziness: 30.6% (vs 8.2% placebo) - most common 3
• Nausea: 11.4% (vs 4.4% placebo) 3
• Diplopia: 10.5% (vs 1.9% placebo) 3
• Headache: 17.1% 4
• Somnolence: 10.2% (vs 3.8% placebo) 8

Most adverse effects are mild to moderate in severity, with severe events predominantly observed at 600 mg/day 3. The incidence of adverse effects is notably lower during the maintenance phase compared to titration 3.

Drug Interactions

Lacosamide has minimal clinically significant drug interactions due to lack of CYP450 enzyme induction or inhibition 5. However:

• Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital) significantly alter lacosamide pharmacokinetics and may require dose adjustment 6
• Discontinuation rates when combined with common AEDs: carbamazepine (15.3%), lamotrigine (19.2%), levetiracetam (10.1%) 3

Special Populations

Elderly Patients (≥65 years)

• Retention rates comparable to younger adults: 68.9% for conversion to monotherapy 9
• Seizure freedom rates: 68% at 6 months, 56.3% at 12 months 9
• Half-life slightly longer (14-16 hours vs 13 hours), but no dose adjustment needed 5
• Consider TDM in this population 6

Renal Impairment

• Dose adjustment required for severe renal dysfunction 6
• Dialysis patients require special consideration and potential TDM 6

Efficacy Benchmarks

Expected outcomes at 400 mg/day:

• ≥50% seizure reduction: 38-41% of patients 1
• ≥75% seizure reduction: Higher rates than placebo 8
• Seizure freedom: 5.6% at 24 months in long-term studies 4
• Particularly effective for secondarily generalized tonic-clonic seizures: 59.4% median reduction at 400 mg/day 1